Monoclonal Antibodies

Amgen is currently investigating antibodies targeting specific biomarkers and continues to expand its pipeline in next generation medicine.

FGFR2b

Amgen is developing a potential first-in-class targeted antibody for people with gastric and gastroesophageal junction (G/GEJ) cancers, otherwise known as stomach cancer, that overexpress a growth receptor called FGFR2b. Despite treatment advances, prognosis remains poor for many patients with advanced G/GEJ.1 FGFR2b is a compelling target, given this protein is overexpressed in 20%-30% of patients with advanced G/GEJ cancer.2,*

References

  1.  Sato Y, Okamoto K, Kawano Y, et al. Novel biomarkers of gastric cancer: Current research and future perspectives. J Clin Med. 2023;12:4646.
  2. Wainberg ZA, Enzinger PC, Kang Y-K, et al. Lancet Oncol. 2022;23:1430-1440.
  3. * Approximate range from a phase 2 trial in locally advanced or metastatic G/GEJ cancer patients.  Of 910 prescreened patients, 274 (30%) were positive for FGFR2b any 2+/3+ tumor cell staining by IHC.  155 of the any 2+/3+ positives underwent further testing with 96 (62%) exhibiting FGFR2b ≥ 10% 2+/3+ tumor cell staining by IHC; 62% extrapolated to the 274 any 2+/3+ positives estimates to ~20%.